Chemotherapy-induced nausea and vomiting is less controlled at delayed phase in patients with esophageal cancer: A prospective registration study by the CINV Study Group of Japan

Yoshifumi Baba, Hideo Baba, Sachiko Yamamoto, Hideaki Shimada, Tomotaka Shibata, Tatsuya Miyazaki, Takaki Yoshikawa, Yasuaki Nakajima, Yasushi Tsuji, Mototsugu Shimokawa, Yuukou Kitagawa, Keisuke Aiba

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Chemotherapy is an indispensable therapeutic approach for esophageal cancer. Although chemotherapy-induced nausea and vomiting (CINV) is one of the most crucial adverse events, the current state of CINV in patients with esophageal cancer remains unclear. This multicenter prospective observational study analyzed data for 192 patents with esophageal cancer who underwent moderately emetogenic chemotherapy (MEC) or highly emetogenic chemotherapy (HEC). The patients recorded their CINV incidence and severity daily for 7 days after receiving chemotherapy, using visual analog scales (VAS). Of the 192 patients, 181 received HEC including cisplatin, and 11 patients received MEC including nedaplatin. Approximately 81% of HEC and 82% of MEC patients received antiemetic therapy in compliance with guidelines. Although CINV was controlled relatively well in the early phase (days 1-4), it was not fully controlled in late phase (days 5-7) for both the HEC and MEC groups. Female sex was a major risk factor for delayed vomiting (P=0.034). Multivariate logistic regression analysis for VAS revealed that motion sickness, age, and use of other antiemetics were risk factors for delayed nausea. Adherence to antiemetic guidelines effectively controls vomiting but is less effective against delayed CINV in both HEC and MEC patients. Identification of individual risk factors, such as female sex, will help develop personalized treatments for CINV. In the clinical setting for esophageal cancer, regimens that include nedaplatin might need to be treated as HEC.

Original languageEnglish
JournalDiseases of the Esophagus
DOIs
Publication statusAccepted/In press - 2016

Fingerprint

Esophageal Neoplasms
Nausea
Vomiting
Japan
Prospective Studies
Drug Therapy
Antiemetics
Visual Analog Scale
Guidelines
Motion Sickness
Patents

Keywords

  • Antiemetic guidelines
  • Antiemetics
  • Chemotherapy
  • CINV
  • Esophageal cancer

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Chemotherapy-induced nausea and vomiting is less controlled at delayed phase in patients with esophageal cancer : A prospective registration study by the CINV Study Group of Japan. / Baba, Yoshifumi; Baba, Hideo; Yamamoto, Sachiko; Shimada, Hideaki; Shibata, Tomotaka; Miyazaki, Tatsuya; Yoshikawa, Takaki; Nakajima, Yasuaki; Tsuji, Yasushi; Shimokawa, Mototsugu; Kitagawa, Yuukou; Aiba, Keisuke.

In: Diseases of the Esophagus, 2016.

Research output: Contribution to journalArticle

Baba, Yoshifumi ; Baba, Hideo ; Yamamoto, Sachiko ; Shimada, Hideaki ; Shibata, Tomotaka ; Miyazaki, Tatsuya ; Yoshikawa, Takaki ; Nakajima, Yasuaki ; Tsuji, Yasushi ; Shimokawa, Mototsugu ; Kitagawa, Yuukou ; Aiba, Keisuke. / Chemotherapy-induced nausea and vomiting is less controlled at delayed phase in patients with esophageal cancer : A prospective registration study by the CINV Study Group of Japan. In: Diseases of the Esophagus. 2016.
@article{3c40df2925944376ac2f1d998104df93,
title = "Chemotherapy-induced nausea and vomiting is less controlled at delayed phase in patients with esophageal cancer: A prospective registration study by the CINV Study Group of Japan",
abstract = "Chemotherapy is an indispensable therapeutic approach for esophageal cancer. Although chemotherapy-induced nausea and vomiting (CINV) is one of the most crucial adverse events, the current state of CINV in patients with esophageal cancer remains unclear. This multicenter prospective observational study analyzed data for 192 patents with esophageal cancer who underwent moderately emetogenic chemotherapy (MEC) or highly emetogenic chemotherapy (HEC). The patients recorded their CINV incidence and severity daily for 7 days after receiving chemotherapy, using visual analog scales (VAS). Of the 192 patients, 181 received HEC including cisplatin, and 11 patients received MEC including nedaplatin. Approximately 81{\%} of HEC and 82{\%} of MEC patients received antiemetic therapy in compliance with guidelines. Although CINV was controlled relatively well in the early phase (days 1-4), it was not fully controlled in late phase (days 5-7) for both the HEC and MEC groups. Female sex was a major risk factor for delayed vomiting (P=0.034). Multivariate logistic regression analysis for VAS revealed that motion sickness, age, and use of other antiemetics were risk factors for delayed nausea. Adherence to antiemetic guidelines effectively controls vomiting but is less effective against delayed CINV in both HEC and MEC patients. Identification of individual risk factors, such as female sex, will help develop personalized treatments for CINV. In the clinical setting for esophageal cancer, regimens that include nedaplatin might need to be treated as HEC.",
keywords = "Antiemetic guidelines, Antiemetics, Chemotherapy, CINV, Esophageal cancer",
author = "Yoshifumi Baba and Hideo Baba and Sachiko Yamamoto and Hideaki Shimada and Tomotaka Shibata and Tatsuya Miyazaki and Takaki Yoshikawa and Yasuaki Nakajima and Yasushi Tsuji and Mototsugu Shimokawa and Yuukou Kitagawa and Keisuke Aiba",
year = "2016",
doi = "10.1111/dote.12482",
language = "English",
journal = "Diseases of the Esophagus",
issn = "1120-8694",
publisher = "Wiley-Blackwell",

}

TY - JOUR

T1 - Chemotherapy-induced nausea and vomiting is less controlled at delayed phase in patients with esophageal cancer

T2 - A prospective registration study by the CINV Study Group of Japan

AU - Baba, Yoshifumi

AU - Baba, Hideo

AU - Yamamoto, Sachiko

AU - Shimada, Hideaki

AU - Shibata, Tomotaka

AU - Miyazaki, Tatsuya

AU - Yoshikawa, Takaki

AU - Nakajima, Yasuaki

AU - Tsuji, Yasushi

AU - Shimokawa, Mototsugu

AU - Kitagawa, Yuukou

AU - Aiba, Keisuke

PY - 2016

Y1 - 2016

N2 - Chemotherapy is an indispensable therapeutic approach for esophageal cancer. Although chemotherapy-induced nausea and vomiting (CINV) is one of the most crucial adverse events, the current state of CINV in patients with esophageal cancer remains unclear. This multicenter prospective observational study analyzed data for 192 patents with esophageal cancer who underwent moderately emetogenic chemotherapy (MEC) or highly emetogenic chemotherapy (HEC). The patients recorded their CINV incidence and severity daily for 7 days after receiving chemotherapy, using visual analog scales (VAS). Of the 192 patients, 181 received HEC including cisplatin, and 11 patients received MEC including nedaplatin. Approximately 81% of HEC and 82% of MEC patients received antiemetic therapy in compliance with guidelines. Although CINV was controlled relatively well in the early phase (days 1-4), it was not fully controlled in late phase (days 5-7) for both the HEC and MEC groups. Female sex was a major risk factor for delayed vomiting (P=0.034). Multivariate logistic regression analysis for VAS revealed that motion sickness, age, and use of other antiemetics were risk factors for delayed nausea. Adherence to antiemetic guidelines effectively controls vomiting but is less effective against delayed CINV in both HEC and MEC patients. Identification of individual risk factors, such as female sex, will help develop personalized treatments for CINV. In the clinical setting for esophageal cancer, regimens that include nedaplatin might need to be treated as HEC.

AB - Chemotherapy is an indispensable therapeutic approach for esophageal cancer. Although chemotherapy-induced nausea and vomiting (CINV) is one of the most crucial adverse events, the current state of CINV in patients with esophageal cancer remains unclear. This multicenter prospective observational study analyzed data for 192 patents with esophageal cancer who underwent moderately emetogenic chemotherapy (MEC) or highly emetogenic chemotherapy (HEC). The patients recorded their CINV incidence and severity daily for 7 days after receiving chemotherapy, using visual analog scales (VAS). Of the 192 patients, 181 received HEC including cisplatin, and 11 patients received MEC including nedaplatin. Approximately 81% of HEC and 82% of MEC patients received antiemetic therapy in compliance with guidelines. Although CINV was controlled relatively well in the early phase (days 1-4), it was not fully controlled in late phase (days 5-7) for both the HEC and MEC groups. Female sex was a major risk factor for delayed vomiting (P=0.034). Multivariate logistic regression analysis for VAS revealed that motion sickness, age, and use of other antiemetics were risk factors for delayed nausea. Adherence to antiemetic guidelines effectively controls vomiting but is less effective against delayed CINV in both HEC and MEC patients. Identification of individual risk factors, such as female sex, will help develop personalized treatments for CINV. In the clinical setting for esophageal cancer, regimens that include nedaplatin might need to be treated as HEC.

KW - Antiemetic guidelines

KW - Antiemetics

KW - Chemotherapy

KW - CINV

KW - Esophageal cancer

UR - http://www.scopus.com/inward/record.url?scp=84962579401&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84962579401&partnerID=8YFLogxK

U2 - 10.1111/dote.12482

DO - 10.1111/dote.12482

M3 - Article

C2 - 27001532

AN - SCOPUS:84962579401

JO - Diseases of the Esophagus

JF - Diseases of the Esophagus

SN - 1120-8694

ER -